OCUL
Ocular Therapeutix Inc
9.70$
-1.7%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2,654.9% | -1,928.2% | -1,801.9% | -2,624.7% | -2,473.7% | -1,835.3% | -307.7% | -150.6% | -115.7% | -120.2% | -211.3% | -395.4% | |
| 70.9% | 43.1% | 46.7% | 84.5% | 114.9% | 59.9% | 15.9% | 5.6% | 4.1% | 5.1% | 5.9% | 8.3% | |
| 342.5% | 265.1% | 315.6% | 380.7% | 376.0% | 207.2% | 43.3% | 34.4% | 32.9% | 30.5% | 52.0% | 83.3% | |
| 342.5% | 245.7% | 380.9% | 380.3% | 376.0% | 105.4% | 538.5% | -134.5% | 6.1% | – | – | – | |
| 280.1% | 28.7% | 110.0% | 184.6% | 29.4% | -44.4% | 6.8% | -6.7% | 2.6% | -12.7% | -16.1% | 14.9% | |
| 163.2% | 101.6% | 101.7% | 429.1% | 94.9% | 52.9% | 4.8% | 2.7% | 7.2% | 10.4% | 2.0% | 23.2% | |
| -4,998.2% | -2,203.9% | 1,884.9% | 1,407.5% | -94.9% | -52.9% | -4.8% | -2.7% | -7.2% | -10.4% | -2.0% | -22.9% | |
| 1,931.6% | 120.2% | 0.0% | 228.0% | 14.9% | 881.8% | 4.3% | 1.6% | – | 89.9% | – | – | |
| 8.3% | 14.2% | 58.5% | 14.4% | 14.9% | 10.7% | 4.3% | 2.3% | 1.8% | 1.5% | 1.6% | 3.1% | |
| 1,602.5% | 22.7% | 127.2% | 124.8% | 320.4% | 881.8% | -2.6% | -1.0% | 0.0% | 96.4% | 0.0% | 0.0% | |
| 10,229.3% | 3,754.5% | 31.0% | 1,664.5% | 3,449.2% | 1,782.4% | 1,310.2% | 6.6% | 2.8% | 290.6% | 521.2% | 1,083.9% | |
| 2,576.2% | -377.7% | 114.0% | 447.3% | 880.6% | -105.9% | 997.6% | -146.8% | -120.1% | 160.0% | 307.8% | 665.6% | |
| -2,818.1% | -2,029.8% | -1,903.6% | -3,053.8% | -2,568.6% | -1,888.2% | -312.6% | -153.4% | -123.0% | -130.6% | -213.4% | -418.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.